上交所公告，自2025年10月29日13时01分开始暂停C禾元（688765）交易，自2025年10月29日13时11分 起恢复交易。 ...

Core Viewpoint - He Yuan Bio's recombinant human albumin, derived from genetically modified rice, is positioned to challenge both domestic and international blood product giants, despite the company currently being unprofitable and facing significant market competition [2][3][7]. Group 1: Company Overview - He Yuan Bio (688765.SH) has recently listed on the Sci-Tech Innovation Board after a two-year suspension, marking the restart of the "fifth set" rules [3]. - The company has incurred losses of 480 million yuan over the past three years, with its success hinging on the profitability of its rice-derived blood products [3]. - The IPO price was set at 29.06 yuan per share, aiming to raise approximately 2.6 billion yuan, with 1.657 billion yuan allocated for the establishment of a recombinant human albumin industrialization base [4]. Group 2: Product Details - The core product is "rice blood," a plant-based recombinant human albumin, which is currently the only commercialized product of He Yuan Bio [3]. - The product is priced at 890 yuan for a 10g (20%, 50mL) bottle, which is more than double the price of human blood albumin available in the market [3][15]. - The market for human serum albumin in China was valued at 25.8 billion yuan in 2020, with projections to reach 57 billion yuan by 2030 [10]. Group 3: Market Position and Competition - He Yuan Bio aims to capture nearly 20% of the domestic market for human albumin, which is currently dominated by imported products [5][11]. - The company’s product is positioned as a safer alternative to human-derived albumin, eliminating risks associated with bloodborne pathogens [14]. - Despite the claimed cost advantages, the current pricing strategy suggests that He Yuan Bio's product is more expensive than traditional human blood albumin [15][16]. Group 4: Future Prospects - He Yuan Bio plans to expand its market presence, with a focus on entering the U.S. market and completing clinical trials for additional indications [12]. - The company has established a production line with an annual capacity of 10 tons and plans to expand to 120 million tons by 2026 [10]. - The company is also developing other products using the same technology, including recombinant human lactoferrin and α-1 antitrypsin [19].

Core Viewpoint - He Yuan Bio, an unprofitable innovative pharmaceutical company, has listed on the Sci-Tech Innovation Board, aiming to challenge domestic and international blood product giants with its unique plant-based recombinant human albumin derived from rice [1][2]. Group 1: Company Overview - He Yuan Bio's core product is "rice-derived blood," specifically the world's first plant-based recombinant human albumin, which is currently its only commercialized product [1]. - The company has incurred losses of 480 million yuan over the past three years, and its ability to achieve profitability hinges on the success of its rice-derived albumin [1]. - The IPO price was set at 29.06 yuan per share, with plans to raise approximately 2.6 billion yuan, of which 1.657 billion yuan is allocated for building an industrialization base for recombinant human albumin [1]. Group 2: Market Position and Competition - He Yuan Bio aims to capture nearly 20% of the domestic human albumin market, which is valued at 258 billion yuan in 2020 and projected to reach 570 billion yuan by 2030 [3][4]. - The company has established a commercial production line with an annual capacity of 10 tons and plans to expand to 120 tons by 2026 [3]. - The current market for human albumin in China is heavily reliant on imports, with imported products accounting for 66% of the market as of mid-2025 [3][4]. Group 3: Product Pricing and Cost Structure - He Yuan Bio's recombinant human albumin is priced at 890 yuan per 10g (20%, 50mL) bottle, which is more than double the price of human-derived albumin, typically priced between 350-400 yuan [2][6]. - The company claims that its plant-based albumin production will eventually lower costs compared to plasma-derived products, with a projected price of around 38 yuan/g once it enters the market [7]. - The company is actively seeking to have its product included in the medical insurance directory to enhance market access and affordability [7]. Group 4: Clinical Development and Future Plans - Currently, He Yuan Bio's recombinant human albumin has only one approved indication for treating liver cirrhosis with low albumin levels, which represents about 30% of the overall market [4][5]. - The company is focused on expanding its clinical trials in the U.S., with plans to complete Phase III trials by 2025 and submit for market approval in 2026 [5]. - Other products in development include recombinant human lactoferrin and recombinant human α-1 antitrypsin, with ongoing clinical trials for various indications [8].

北京商报讯（记者 丁宁）10月29日，禾元生物（688765）盘中股价不断上攻，一度涨逾25%。 截至北京商报记者发稿，禾元生物报113.88元/股，涨幅达25.01%。 ...

Core Viewpoint - He Yuan Bio, an unprofitable innovative pharmaceutical company, has listed on the Sci-Tech Innovation Board, challenging domestic and international blood product giants with its unique plant-based recombinant human albumin derived from rice [2][3]. Company Overview - He Yuan Bio's core product is "rice-derived blood," specifically the world's first plant-based recombinant human albumin, which is currently its only commercialized product. The company has incurred losses of 480 million yuan over the past three years [2]. - The IPO price was set at 29.06 yuan per share, aiming to raise approximately 2.6 billion yuan, with 1.657 billion yuan allocated for the construction of an industrialization base for recombinant human albumin [2]. Market Potential - The recombinant human albumin market in China was valued at 25.8 billion yuan in 2020, with projections of reaching 57 billion yuan by 2030. He Yuan Bio aims to capture nearly 20% of the domestic market [4]. - The company has established a commercial production line with an annual capacity of 10 tons and plans to expand to 120 tons by 2026 [4]. Competitive Landscape - He Yuan Bio's plant-based recombinant human albumin directly competes with human-derived blood products and aims to address the limited domestic blood plasma supply, which has led to a reliance on imports [3][4]. - The company claims that its product is safer due to the absence of blood plasma donation and has comparable efficacy to human-derived albumin [6]. Pricing Strategy - The current market price for He Yuan Bio's recombinant human albumin is 890 yuan per 10g, significantly higher than the 350-400 yuan range for human-derived products [6][9]. - The company anticipates that production costs will decrease with scale, and it plans to apply for inclusion in the medical insurance directory to potentially lower prices further [9]. Product Development - He Yuan Bio is currently focused on the clinical trial for its recombinant human albumin, with plans to complete Phase III trials in the U.S. by 2025 and submit for market approval in 2026 [5]. - Other products in development include recombinant human lactoferrin and recombinant human α-1 antitrypsin, with ongoing clinical trials for various indications [10].

北京商报讯（记者丁宁）10月29日，禾元生物（688765）低开高走，盘中一度涨近12%。 交易行情显示，禾元生物10月29日低开1.2%，开盘价为90.01元/股，盘中最高触及102.18元/股。截至北 京商报记者发稿，禾元生物报100.2元/股，涨幅为9.99%。 值得一提的是，禾元生物于10月28日上市，上市首日，公司股票大幅收涨213.49%。 ...

Core Insights - The financing balance of the Sci-Tech Innovation Board increased by 989 million yuan compared to the previous day, with 81 stocks seeing an increase of over 10 million yuan in financing balance [1] - As of October 28, the total margin financing balance on the Sci-Tech Innovation Board reached 259.614 billion yuan, marking a daily increase of 1.011 billion yuan, continuing a trend of increases for three consecutive trading days [1] - The stocks with the highest net financing purchases included C He Yuan, C Yi Cai, and Ju Chen Co., with significant increases in their financing balances and corresponding stock price rises [2] Financing Balance Summary - The total margin financing balance on the Sci-Tech Innovation Board is 259.614 billion yuan, with a financing balance of 258.678 billion yuan [1] - There are 474 stocks with a financing balance exceeding 100 million yuan, and 45 stocks with a financing balance over 1 billion yuan [1] - Newly listed stocks on October 28, C He Yuan and C Yi Cai, had initial financing balances of 269 million yuan and 251 million yuan, respectively [1] Net Financing Purchases - C He Yuan had the highest net financing purchase amounting to 269 million yuan, with a daily increase of 213.49% in stock price [2] - The average increase in stock prices for stocks with net purchases exceeding 10 million yuan was 5.61%, with notable increases for C He Yuan and C Yi Cai [2] - The sectors attracting the most financing interest included electronics, machinery, and power equipment, with 37, 12, and 9 stocks respectively [2] Financing Balance Proportions - The average financing balance as a percentage of the circulating market value for stocks with significant net purchases is 4.36% [2] - Tian Cheng Technology had the highest financing balance proportion at 11.57%, with a financing balance of 458 million yuan [2]

Group 1 - The core point of the news is that He Yuan Bio experienced a significant stock price increase of 213.49% on October 28, with a trading volume of 2.782 billion yuan [1] - On the same day, He Yuan Bio had a financing buy amount of 369 million yuan, with a net financing purchase of 269 million yuan, indicating strong investor interest [1] - The company's total financing and securities balance reached 269 million yuan, accounting for 7.21% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio increased to 47,100, a rise of 84,075% compared to the previous period [2] - The average circulating shares per person decreased to 869 shares, a drop of 99.85% from the previous period [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.6608 million yuan, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the growth tier of the board, with significant initial trading performance [1][2]. Group 1: Company Overview - Heyuan Biotechnology was established in 2006 and is recognized as an innovative enterprise [1]. - The company has developed a recombinant human albumin injection derived from rice, which is the first of its kind globally to receive regulatory approval and has begun sales [1][2]. Group 2: Financial Performance - On its first trading day, Heyuan Biotechnology opened at a price of 88 yuan per share, reflecting a 202.82% increase from the issue price of 29.06 yuan, and closed at 91.10 yuan, a total increase of 213.49% [1]. - The total amount raised from the public offering was 2.6 billion yuan, with a net amount of 2.43 billion yuan after deducting issuance costs [2]. Group 3: Use of Proceeds - The funds raised will primarily be allocated to the construction of a recombinant human albumin industrialization base, new drug research and development, and to supplement working capital [1][2]. - The company has established a production line capable of producing 1 million bottles annually and is currently building a facility expected to produce 12 million bottles of recombinant human serum albumin injection per year, which will help reduce reliance on imports [2].

Core Viewpoint - The chairman and general manager of He Yuan Bio expressed that the company will accelerate the progress of its international clinical pipelines following its listing on the STAR Market [1] Company Overview - He Yuan Bio has a total of 8 drug pipelines currently under research [1] - The core product, recombinant human albumin injection (HY1001), is expected to be approved for market by July 2025, targeting the indication of "hypoalbuminemia due to liver cirrhosis" [1] - In addition to the core product, 5 other products are in clinical research stages, while multiple products are in preclinical research stages [1]